Search company, investor...

Predict your next investment

Venture Capital
one-ventures.com.au

Investments

87

Portfolio Exits

3

Funds

5

About OneVentures

OneVentures is a venture capital firm that invests in emerging Australian technology companies with true breakout potential, differentiated technology and compelling business models in the clean technology, information technology and life sciences sectors.

Headquarters Location

179 Elizabeth Suite 13.02

Sydney, New South Wales, 2000,

Australia

+61 2 8205 7379

Want to inform investors similar to OneVentures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest OneVentures News

This biotech working on needle-free COVID-19 vaccine downs $23M funding

Dec 7, 2022

We have all heard about this Dutch startup working on Covid-19 vaccine patch to replace injectable jabs . Now recently, Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccine platform, announced it had raised $23 million in new funding. The investment round was led by existing investors OneVentures and UniQuest Pty Ltd. New investors include members of the Vaxxas Board of Directors, the management team, and several individual investors. This financing will be used to advance Vaxxas’ clinical programs, including its needle-free COVID-19 vaccine candidate, and to build Vaxxas’ first manufacturing line, which will support the company’s first products through late-stage clinical trials and early commercial production. “Our confidence has only been reinforced by Vaxxas’ tremendous progress in building a promising clinical pipeline based on its novel HD-MAP vaccination platform,” revealed Dr Paul Kelly, Founding Partner and Head of Healthcare at OneVentures. “We believe Vaxxas’ needle-free vaccination technology will dramatically improve the availability, efficacy, and safety of vaccines for a range of serious and prevalent diseases, including COVID-19 and influenza. We are pleased to continue supporting the Vaxxas team through this pivotal time in the company’s growth – as it applies a breakthrough approach to address some of the most significant unmet global needs in infectious and potentially other diseases.” The financing will accelerate the clinical program for Vaxxas’ COVID-19 vaccine patch candidate which is currently in Phase I clinical trials and is based upon the company’s proprietary HD-MAP delivery of HexaPro, a second-generation version of the spike protein used in all major US-approved COVID-19 vaccines. Results from preclinical animal studies of HD-MAP delivered HexaPro published in Science Advances, showed the potential efficacy of this COVID-19 vaccine patch against all currently known variants of concern. “This financing from a strong syndicate of experienced life science investors reflects the significant potential of our considerable product pipeline and novel needle-free vaccination technology,” said David Hoey, Chief Executive Officer of Vaxxas. “With a strong foundation to our HD-MAP platform, we are well positioned to advance multiple product opportunities toward commercial launch. In the near-term, we will continue to advance our lead COVID-19 vaccine program along with other clinical initiatives, and execute our go-to-market strategy of building commercial-scale manufacturing capacity and high throughput production lines.” This $23 million in new funding will leverage non-dilutive financial support of more than $67 million which has been provided and committed to Vaxxas under contracts with US and Australian government agencies, including US Biomedical Advanced Research and Development Authority (BARDA), industry collaborators, and global health organisations, including the World Health Organization (WHO) and the Bill and Melinda Gates Foundation. Vaxxas was founded in 2011 by UniQuest, a major shareholder in Vaxxas, which was developed at The University of Queensland (UQ). Board Of Directors. Dr. Paul Kelly is a Founder and Managing Partner of OneVentures and serves on the investment committee of OneVentures’ three main Funds, chairing the Healthcare Fund III Investment Committee, and leads the healthcare and biotechnology practice across the firm.

OneVentures Investments

87 Investments

OneVentures has made 87 investments. Their latest investment was in Vaxxas as part of their Series C on December 12, 2022.

CBI Logo

OneVentures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/5/2022

Series C

Vaxxas

$23M

No

OneVentures, Undisclosed Angel Investors, and Uniquest

12

11/15/2022

Series B

Buildkite

$21M

Yes

14

7/25/2022

Debt

XY Sense

$2M

Yes

1

7/14/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

2/16/2022

Series F

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/5/2022

11/15/2022

7/25/2022

7/14/2022

2/16/2022

Round

Series C

Series B

Debt

Series B

Series F

Company

Vaxxas

Buildkite

XY Sense

Subscribe to see more

Subscribe to see more

Amount

$23M

$21M

$2M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

OneVentures, Undisclosed Angel Investors, and Uniquest

Sources

12

14

1

10

10

OneVentures Portfolio Exits

3 Portfolio Exits

OneVentures has 3 portfolio exits. Their latest portfolio exit was Smart Sparrow on January 22, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/22/2020

Acquired

$99M

2

11/6/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

3/5/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/22/2020

11/6/2019

3/5/2018

Exit

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

10

10

OneVentures Fund History

5 Fund Histories

OneVentures has 5 funds, including 1V Venture Credit Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/22/2020

1V Venture Credit Fund

$80M

2

4/12/2019

OneVentures Credit Fund

$99M

10

12/17/2015

OneVentures Innovation and Growth Fund II

$99M

10

12/31/2010

OneVentures Innovation Fund

$99M

0

OneVentures Healthcare Fund III

0

Closing Date

7/22/2020

4/12/2019

12/17/2015

12/31/2010

Fund

1V Venture Credit Fund

OneVentures Credit Fund

OneVentures Innovation and Growth Fund II

OneVentures Innovation Fund

OneVentures Healthcare Fund III

Fund Type

Status

Amount

$80M

$99M

$99M

$99M

Sources

2

10

10

0

0

OneVentures Team

4 Team Members

OneVentures has 4 team members, including , .

Name

Work History

Title

Status

Anne Marie Birkill

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Anne Marie Birkill

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.